PCSK9s - Contracting for Competitive Advantage : IC Fireside Chats - Episode 9
PCSK9 inhibitors came with clinical promise — and a pricing problem. Unlike low-cost oral medicines, these were high-priced subcutaneous injections aimed at long-term prevention, not short-term outcomes.
While some manufacturers struggled to gain traction, one took a different route: using a value-based agreement not just to justify cost, but to earn credibility.
In this episode, Omar Ali and Adam Buckler unpack how a well-designed VBA created real competitive advantage — securing payer trust, accelerating access, and outpacing the competition.
We explore:
Why traditional pricing approaches fell flat
How outcome-based guarantees addressed payer hesitation
What this case tells us about contracting strategy for chronic conditions
This conversation highlights how contracting isn’t just about unlocking access — it’s about creating shared confidence, managing uncertainty, and building the conditions for long-term success.
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
